Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895180 · ClinicalTrials.gov registry record · Phase 2
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
A Phase 2 study of Adult Glioblastoma Multiforme, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT00895180: Completed Phase 2 study of Adult Glioblastoma Multiforme, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00895180 is a Phase 2 study of Adult Glioblastoma Multiforme that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00895180, a Phase 2 study of Adult Glioblastoma Multiforme, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 works in treating patients with recurrent glioblastoma multiforme.
Primary Outcome
PFS was defined as the start of treatment to the earliest date of tumor progression or death from any cause based on the modified Response Assessment in Neuro-Oncology Group through the American Society of Clinical Oncology (RANO) criteria. Progression is defined by any of the following: ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration. RANO is a standardized response criteria using bi-dimensional measurements of the
Conditions Studied
Interventions
- BIOLOGICAL ramucirumab
- BIOLOGICAL olaratumab
Study Locations (11)
California
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
- University of California San Francisco Medical Center - San Francisco
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Florida
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-03-04 |
| Phase | Phase 2 |
What the finished NCT00895180 record still lists
NCT00895180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Adult Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which ramucirumab is the first listed.
NCT00895180 lists 11 locations in 10 states (California, Alabama, Florida).
Frequently Asked Questions
What is clinical trial NCT00895180 about?
NCT00895180 is a clinical study titled "Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme". RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to the...
What is the current status of trial NCT00895180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2010-07. Estimated completion is 2014-03-04.
What conditions does trial NCT00895180 study?
This clinical trial studies the following conditions: Adult Glioblastoma Multiforme.
What interventions are being tested in trial NCT00895180?
The interventions under investigation include: ramucirumab (BIOLOGICAL), olaratumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00895180?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00895180 being conducted?
This trial has 11 study locations across Alabama, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00895180's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia